Synaptogenix Inc (SNPX)

[SF Wolf]

The key to understanding what NTRP is investigating is in these two paragraphs:

Dr.Alkon:
“In contrast, the loss of synaptic networks has been found, with numerous autopsy studies, to correlate with the severity of cognitive dysfunction and disease progression,” he said. “We at Neurotrope believe that the regenerative effects of Bryostatin’s treatment on the synapses, as well as Bryostatin’s prevention of amyloid and plaque deposition, may not just reduce but potentially reverse the symptoms by addressing for the first time many of the major early causes of this devastating disease.”

Bryostatin-1 is a protein kinase C (PKC) modulator. Neurotrope said that in studies with Alzheimer’s animal models, it was shown to be effective for restorative synaptogenesis (generation of new synapses, or connections between neurons), prevention of neuronal death, and anti-amyloid, anti-tau metabolism (the two proteins connected to Alzheimer’s), offering the potential to improve cognition, memory and behavior in patients.

NTRP is way ahead of any other company in taking this approach.